EMA Application withdrawn: Zafiride — MolMed SpA

View source ↗

Summary

The EMA withdrew the application for Zafiride by MolMed SpA; the therapeutic area was mesothelioma and the status indicates the application was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma

Drugs mentioned

• Zafiride

Snippet

Status: Application withdrawn. Therapeutic area: Mesothelioma. MAH: MolMed SpA. Decision date: 23/06/2017. Orphan medicine